Differential effects of priming with DNA vaccines encoding the hemagglutinin and/or fusion proteins on cytokine responses after measles virus challenge

Journal of Infectious Diseases

Volumn 187, Issue 11, 2003, Pages 1794-1800

  Polack, Fernando P ^a,b   Hoffman, Scott J ^a   Moss, William J ^a   Griffin, Diane E ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA VACCINE; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 12; INTERLEUKIN 4; MEASLES VACCINE; PLASMID DNA; VIRUS ANTIGEN; VIRUS HEMAGGLUTININ; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; IMMUNOMODULATION; INTERFERON PRODUCTION; MEASLES; MEASLES VACCINATION; MEASLES VIRUS; NONHUMAN; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; RHESUS MONKEY; SECONDARY IMMUNE RESPONSE;

ANIMALS; CYTOKINES; HEMAGGLUTININS, VIRAL; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-4; MACACA MULATTA; MEASLES; MEASLES VACCINE; MEASLES VIRUS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, DNA; VIRAL FUSION PROTEINS;

EID: 0038540535     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/375245     Document Type: Article

References (38)

1. Griffin DE. In: Knipe DM, Howley PM, eds. Fields virology. 4th ed. New York: Raven Press, 2001:1401.
2. Albrecht P, Ennis FA, Saltzman EJ, Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr 1977; 91:715-8.
3. Halsey NA, Boulos R, Mode F, et al. Response to measles vaccine in Haitian infants 6 to 12 months old: influence of maternal antibodies, malnutrition, and concurrent illnesses. N Engl J Med 1985; 313:544-9.
4. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998; 280:527-32.
5. Garenne M, Leroy O, Beau J-P, Sene I. Child mortality after high-titre measles vaccine: prospective study in Senegal. Lancet 1991; 338:903-7.
6. Holt EA, Moulton LH, Siberry GK, Halsey NA. Differential mortality by measles vaccine titer and sex. J Infect Dis 1993; 168:1087-96.
7. Polack FP, Hoffman SJ, Griffin DE. Altered synthesis of interleukin-12 and type 1 and type 2 cytokines in rhesus macaques during measles and atypical measles. J Infect Dis 2002; 185:13-9.
8. Atabani SF, Byrnes AA, Jaye A, et al. Natural measles causes prolonged suppression of interleukin-12 production. J Infect Dis 2001; 184:1-9
9. Griffin DE, Ward BJ. Differential CD4 T cell activation in measles. J Infect Dis 1993; 168:275-81.
10. Karp CL, Wysocka M, Wahl LM, et al. Mechanism of suppression of cell-mediated immunity by measles virus. Science 1996; 273:228-31.
11. Fugier-Vivier I, Servet-Delprat C, Rivailler P, et al. Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. J Exp Med 1997; 186:813-23.
12. + T cells. J Exp Med 1997; 186:801-12.
13. Carter CH, et al. Serologic response of children to inactivated measles vaccine. JAMA 1962; 179:848-53.
14. Fulginiti VA, Eller JJ, Downie AW, Kempe CH. Altered reactivity to measles virus: atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 1967; 202:1075.
15. Nader PR, Honwitz MS, Rousseau J. Atypical exanthem following exposure to natural measles: eleven cases in children previously inoculated with killed vaccine. J Pediatr 1968; 72:22-8.
16. Brodsky AL. Atypical measles: severe illness in recipients of killed virus vaccine upon exposure to natural infection. JAMA 1972; 222:1415-6.
17. Polack FP, Auwaerter PG, Lee SH, et al. Atypical measles: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion inhibiting antibodies. Nature Med 1999; 5:629-34.
18. Norrby E, Gollmar Y. Identification of measles virus-specific hemolysis-inhibiting antibodies separate from hemagglutination-inhibiting antibodies. Infect Immun 1975; 11:231-9.
19. Norrby E, Enders-Ruckle G, ter Meulen V. Differences in the appearance of antibodies to structural components of the measles virus after immunization with inactivated and live virus. J Infect Dis 1975; 132:262-9.
20. Enders-Ruckle G. Some characteristics of immunity following natural measles and various forms of immunization. Arch Gesante Virusforsch 1967; 22:23-4.
21. Sparer TE, Matthews S, Hussell T, et al. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J Exp Med 1998; 187:1921-6.
22. Aaby P, Simondon F, Samb B, et al. Low mortality after mild measles infection compared to uninfected children in rural west Africa. Vaccine 2002; 21:120-6.
23. Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow-up study in Guinea-Bissau. BMJ 2000; 321:1435-8.
24. Polack FP, Lee SH, Permar S, et al. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nature Med 2000;6:776-81.
25. Erlenhofer C, Duprex WP, Rima BK, ter Meulen V, Schneider-Schaulies J. Analysis of receptor (CD46, CD150) usage by measles virus. J Gen Virol 2002; 83:1431-6.
26. Bieback K, Lien E, Klagge IM, et al. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J Virol 2002; 76:8729-36.
27. + functional responses by peptide dose in Th1 and Th2 subsets expressing the same transgenic antigen receptor. Cell Immunol 1993; 148:357-70.
28. + T cell responses: the alternative approaches. Annu Rev Immunol 1997; 15:297-322.
29. Konig B, Streckert HJ, Krusat T, Konig W. Respiratory syncytial virus G-protein modulates cytokine release from human peripheral blood mononuclear cells. J Leukoc Biol 1996; 59:403-6.
30. Graham BS. Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. Am J Resp Crit Care Med 1995; 152:S63.
31. Openshaw PJM. Immunity and immunopathology to respiratory syncytial virus: the mouse model. Am J Resp Crit Care Med 1995; 152:S59.
32. Collins PL, McIntosh K, Chanock RM. Respiratory syncytial virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology. 3rd ed. New York: Raven Press, 1996:1313-51.
33. Openshaw PJ, Clarke SL, Record FM. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol 1992; 4:493.
34. Hancock GE, et al. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol 1996; 70:7783.
35. + T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med 1997; 186:421.
36. + T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. Eur J Immunol 1997; 27:3341.
37. Brossay L, Kronenberg M. Highly conseved antigen-presenting function of CD1d molucules. Immunogenetics 1999; 50:146-51.
38. + T cells produce large amounts of IL-4 and IFN-gamma upon activation by anti-CD3 or CD1. J Immunol 1997; 159:2240-9.